AbbVie received a Complete Response Letter (CRL) from the FDA for its Biologics License Application (BLA) for ...
Regeneron reached an agreement with the U.S. government to link current and future drug prices to those in other developed ...
FDA is formalizing RWD as core evidence, enabling “single pivotal trial plus confirmatory evidence” approaches that may ...
This episode of The Ron Lanton Report explores how geography, policy, and capital are converging to redefine where innovation ...
Cell and gene therapies (CGT) continue to advance in the pharmaceutical industry. Despite continued investment in R&D, the ...
In today’s Pharmaceutical Executive Daily, the FDA expands the use of Tzield to young children to delay the onset of stage 3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results